These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 20623530)

  • 1. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
    Lu J; Liong M; Li Z; Zink JI; Tamanoi F
    Small; 2010 Aug; 6(16):1794-805. PubMed ID: 20623530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
    Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
    Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
    Yan Y; Fu J; Wang T; Lu X
    Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
    She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
    Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
    Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
    Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
    Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
    Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
    Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
    Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
    Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution.
    Baeza A; Manzano M; Colilla M; Vallet-Regí M
    Biomater Sci; 2016 May; 4(5):803-13. PubMed ID: 26902682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review.
    Zhang Y; Lin X; Chen X; Fang W; Yu K; Gu W; Wei Y; Zheng H; Piao J; Li F
    Int J Nanomedicine; 2024; 19():5859-5878. PubMed ID: 38887691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
    Li Z; Zhang Y; Feng N
    Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Mesoporous Silica Nanocarriers in Oncology.
    Baeza A; Vallet-Regi M
    Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective.
    Hosseinpour S; Walsh LJ; Xu C
    J Mater Chem B; 2020 Nov; 8(43):9863-9876. PubMed ID: 33047764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesoporous silica nanoparticles in medicine--recent advances.
    Mamaeva V; Sahlgren C; Lindén M
    Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
    Tang F; Li L; Chen D
    Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable hydrogel imbibed with camptothecin-loaded mesoporous silica nanoparticles as an implantable sustained delivery depot for cancer therapy.
    Min Jung J; Lip Jung Y; Han Kim S; Sung Lee D; Thambi T
    J Colloid Interface Sci; 2023 Apr; 636():328-340. PubMed ID: 36638572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function.
    Pasqua L; Leggio A; Sisci D; Andò S; Morelli C
    Mini Rev Med Chem; 2016; 16(9):743-53. PubMed ID: 26996622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
    Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
    J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.